The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Zetia, a cholesterol-reducing drug, marketed by Merck and Shering Plough, has recently come under scrutiny by the House Committee on Energy and Commerce. The House is investigating the results of a recent clinical trial of Zetia. This clinical trial was designed to confirm Zetia’s ability to reduce the growth of plaque in arteries when combined with another cholesterol drug. Although the clinical trial was conducted in April 2006, the results have yet been released. To read more about this article visit:

Comments are closed.